Vertex to acquire Crinetics in $10 billion deal, adding rare-disease drug Palsonify to its portfolio

Vertex Pharmaceuticals announced a $10 billion transaction to purchase Crinetics Pharmaceuticals. The deal will bring Crinetics' recently launched drug Palsonify into Vertex's portfolio.

Palsonify, introduced last year, is used to treat a rare endocrine disorder. By acquiring the drug, Vertex expands its presence in the rare‑disease market and adds a new therapeutic option for patients.

The acquisition reflects the continued pace of large‑scale M&A activity in the biopharma sector as companies seek to broaden their pipelines and address unmet medical needs.